Sulfur Containing Patents (Class 514/665)
-
Publication number: 20040225021Abstract: The invention provides novel polyamine compounds and pharmaceutical compositions for administration in conjunction with cancer chemotherapy or radiation therapy. The compounds are administered locally to provide protection against the adverse side-effects of chemotherapy or radiation therapy, such as alopecia, mucositis and dermatitis. Pharmaceutical preparations comprising one or more chemoprotective polyamines formulated for topical or local delivery to epithelial or mucosal cells are disclosed. Methods of administering the pharmaceutical preparations are also disclosed.Type: ApplicationFiled: May 17, 2004Publication date: November 11, 2004Applicant: Wisconsin Alumni Research FoundationInventors: William E. Fabl, Richard R. Copp, Cynthia E. Ochsner, Daniel D. Peebles, Kathleen L. Fahl
-
Patent number: 6812251Abstract: The invention provides a method of inhibiting tumor growth by contacting the tumor with a composition containing a taurine compound. The composition is administered to directly contact a tumor cell at a dose sufficient to induce cell death.Type: GrantFiled: March 15, 2002Date of Patent: November 2, 2004Assignee: Rhode Island HospitalInventors: Paul Calabresi, Bai-Chuan Pan, James Darnowski
-
Patent number: 6809117Abstract: The present invention is based on the discovery that nitric oxide (NO) is an important growth regulator in an intact developing organism. In particular, the present invention relates to a method of increasing in a mammal a population of hematopoietic stem cells in bone marrow which are capable of undergoing normal hematopoiesis and differentiation, wherein the bone marrow is contacted with an inhibitor of NO, such as an inhibitor of nitric oxide synthase (NOS), thereby producing bone marrow having an increased population of hematopoietic stem cells which are capable of undergoing normal hematopoiesis and differentiation. The present invention also relates to a method of increasing a population of cells in S phase in a tissue of a mammal, comprising contacting the tissue with an inhibitor of NO, such as an inhibitor of NOS. The invention also pertains to a method of regenerating tissue in an adult mammal comprising contacting a selected tissue (e.g.Type: GrantFiled: November 4, 2002Date of Patent: October 26, 2004Assignee: Cold Spring Harbor LaboratoryInventors: Grigori N. Enikolopov, Natalia I. Peunova, Boris A. Kuzin, Hollis Cline, Tatiyana Michurina
-
Patent number: 6794414Abstract: Diseases Mediated by transglutaminase, such as Huntington's Disease, spinobulbar atrophy, spinocerebellar ataxia, and dentatorubralpallidoluysian atrophy, as well as inflammatory diseases of the central nervous system, including mautiple sclerosis, rheumatoid arthritis, and insulin dependent diabetes mellitus, can be treated by administering a transglutaminase inhibitor such as monadansyl cadaverine, monoamines and diamines such as cystamine, putrescine, GABA. (gamma-amino benzoic acid), N-benzyloxy carbonyl, 5-deazp-4-oxonorvaline p-nitrophenylester, glycine methyl ester, CuSO4, and the oral anti-hyperglycemic agent tolbutamide.Type: GrantFiled: September 6, 2001Date of Patent: September 21, 2004Assignee: Yeda Research and Development Co. Ltd.Inventor: Lawrence Steinman
-
Patent number: 6784209Abstract: Food supplement compositions and their methods of use in increasing lean mass and/or muscle size and/or strength in individuals, particularly, athletes is described. The food supplements described comprise a substance which increases nitric oxide production in the body, and, a source of amino acids. Other food supplements described comprise a substance which can enhance and/or mimic insulin activity, and a source of amino acids. The food supplement compositions described are suitable for supplementing the diet of an athlete and particularly for enhancing an athlete's muscle size or strength.Type: GrantFiled: January 13, 2000Date of Patent: August 31, 2004Assignee: Muscletech Research and Development Inc.Inventors: Paul T. Gardiner, Derek E. Woodgate, Mark S. Gilbert, Robert W. Thoburn
-
Publication number: 20040152770Abstract: The present invention discloses highly packed polycationic ammonium, sulfonium and phosphonium lipid compounds useful for making lipid aggregates for delivery of macromolecules and other compounds into cells. They are especially useful for the DNA-dependent transformation of cells. Methods for their preparation and use as intracellular delivery agents are also disclosed.Type: ApplicationFiled: January 21, 2004Publication date: August 5, 2004Inventors: Alberto Haces, Valentina C. Ciccarone
-
Patent number: 6753323Abstract: The present invention is directed to methods of treating or protecting mucosal tissue from damage associated with radiation and/or chemotherapeutic treatment of cancers, by the topical application of amifostine and related compounds. These methods avoid the side effects of systemically applied radio/chemo protectants. The invention is also directed to treatment and prevention of infections associated with mucositis by topical application of amifostine and related compounds.Type: GrantFiled: March 28, 2001Date of Patent: June 22, 2004Assignee: MedImmune Oncology, Inc.Inventors: Martin Stogniew, Jean Bourhis
-
Publication number: 20040110719Abstract: Methods of preventing or reducing ototoxicity in patients undergoing treatment with therapeutically effective amounts of platinum-containing chemotherapeutic agents such as cisplatin or aminoglycoside antibiotics are provided. The methods comprise administering an effective amount of an otoprotective agent comprising methionine or a methionine-like moiety to said patient prior to, simultaneously with, or subsequently to administration of the platinum-containing chemotherapeutic agent or aminoglycoside antibiotic. Combinations of these time periods can also be employed.Type: ApplicationFiled: October 27, 2003Publication date: June 10, 2004Applicant: Board of Trustees of Southern Illinois UniversityInventor: Kathleen C.M. Campbell
-
Patent number: 6743419Abstract: A method of reducing the rate of mammalian hair growth includes topically applying a composition containing a sulfhydryl reactive compound to the skin.Type: GrantFiled: June 5, 1997Date of Patent: June 1, 2004Assignee: The Gillette CompanyInventors: Douglas Shander, Gurpreet S. Ahluwalia, Diana Marks-Del Grosso
-
Publication number: 20040087567Abstract: The present invention relates to a novel diaminedithiol derivative or a pharmaceutically acceptable salt thereof; radiorhenium or radiotechneticum complex thereof; a composition for treating liver cancer comprising the radiorhenium complex and lipiodol; and, a preparative kit of the composition for treating liver cancer.Type: ApplicationFiled: August 25, 2003Publication date: May 6, 2004Inventors: Jae Min Jeong, Young Ju Kim, Yun-Sang Lee, Dong Soo Lee, June-Key Chung, Myung Chul Lee
-
Publication number: 20040053892Abstract: The invention provides enantiomers of a joene and derivtives of Z(−)-ajoene. The derivative of Z(−)-ajoene are useful for modulating integrin-mediated functions, for treating disorders, diseases or conditions in which integrins play a role, and for treating tissues to improve their condition for a subsequent use, such as transplantation.Type: ApplicationFiled: June 17, 2003Publication date: March 18, 2004Inventors: John B Davidson, Alexander V Tatarintsev, Ali S Turgiev, James E K Hildreth
-
Publication number: 20040048834Abstract: New spisulosine derivatives of use in treating tumors are of the formula (I) wherein: each X is the same or different, and represents H, OH, OR′, SH, SR′, SOR′, SO2R′, NO2, NH2, NHR′, N(R′)2, CN, halogen, C(═O)H, C(═O)CH3, CO2H, CO2CH3, substituted or unsubstituted C1-C18 alkyl, substituted or unsubstituted C2-C18 alkenyl, substituted or unsubstituted C2-C18 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaromatic, or two groups X may together form ═O; Y is NR1, OR1, PR1, SR1, or halogen, wherein the number of substituents R1 is selected to suit the valency and each R1 is independently selected of H, OH, C(═O)R′, P(═O)R′R″, substituted or unsubstituted C1-C18 alkyl, substituted or unsubstituted C2-C18 alkenyl, substituted or unsubstituted C2-C18 alkynyl, substituted or unsubstituted aryl, and wherein the dotted line indicates an optional double bond; each Z is the same different, and represents H, OH,Type: ApplicationFiled: August 18, 2003Publication date: March 11, 2004Inventors: Jose Luis Acena, Javier Adrjo, Carmen Cuevas, Pilar Gallego, Ignacio Manzanares, Simon Munt, Ignacio Rodriguez
-
Publication number: 20040033985Abstract: A method of preparing a composition for regulating animal growth comprising the steps of preparing cysteamine or its salt, and mixing the cysteamine or its salt with cyclodextrin or its derivative in a reactor.Type: ApplicationFiled: September 10, 2003Publication date: February 19, 2004Inventors: Francis Chi, Qin Tang Wen, Jie Chen, Tian Shui Lu
-
Publication number: 20030195184Abstract: The present invention provides a unique approach for the diagnosis and management of infections by Chlamydia species, particularly C. pneumoniae. The invention is based, in part, upon the discovery that a combination of agents directed toward the various stages of the chlamydial life cycle is effective in substantially reducing infection. Products comprising combination of antichlamydial agents, novel compositions and pharmaceutical packs are also described.Type: ApplicationFiled: March 19, 2002Publication date: October 16, 2003Inventors: William M. Mitchell, Charles W. Stratton
-
Publication number: 20030185778Abstract: The invention provides novel polyamine compounds and pharmaceutical compositions for administration in conjunction with cancer chemotherapy or radiation therapy. The compounds are administered locally to provide protection against the adverse side-effects of chemotherapy or radiation therapy, such as alopecia, mucositis and dermatitis. Pharmaceutical preparations comprising one or more chemoprotective polyamines formulated for topical or local delivery to epithelial or mucosal cells are disclosed. Methods of administering the pharmaceutical preparations are also disclosed.Type: ApplicationFiled: February 7, 2003Publication date: October 2, 2003Inventors: William E. Fahl, Richard R. Copp, Cynthia E. Ochsner, Daniel D. Peebles, Kathleen L. Fahl
-
Patent number: 6623724Abstract: Disclosed are methods and compositions for regulating the melanin content of mammalian melanocytes; regulating pigmentation in mammalian skin, hair, wool or fur; treating or preventing various skin and proliferative disorders; by administration of various compounds, including alcohols, diodls and/or triols and their analogues.Type: GrantFiled: May 28, 1998Date of Patent: September 23, 2003Assignee: Applied Genetics Incorporated DermaticsInventors: David A. Brown, Alexander A. Khorlin, Krystyna Lesiak, Wu Yun Ren
-
Publication number: 20030171348Abstract: The present invention provides a unique approach for the diagnosis and management of infections by Chlamydia species, particularly C. pneumoniae. The invention is based, in part, upon the discovery that a combination of agents directed toward the various stages of the chlamydial life cycle is effective in substantially reducing infection. Products comprising combination of antichlamydial agents, novel compositions and pharmaceutical packs are also described.Type: ApplicationFiled: March 19, 2002Publication date: September 11, 2003Inventors: William M. Mitchell, Charles W. Stratton
-
Patent number: 6617356Abstract: Suspensions, emulsions or dispersions of therapeutically active agents which are water insoluble or water intolerant such as nutritional supplements, herbal products, drugs, bacteria, yeast, vitamins and minerals are prepared as suspensions in edible vegetable oils such as orange, lemon, soybean, cotton seed, peanut, canola corn oil, sunflower, safflower, palm kernel, palm and coconut. The active therapeutic agent may be in crystalline or amorphous form, it may be a liquid as for example an oil such as vitamin B or beta carotene, or a preparation of a comminuted plant structure such as flower, parts, leaf; stern, root or tree bark, or an extract of a dried plant structure or a freeze dried preparation of a vital bacteria or yeast. The suspension is formed by active mixing of the active agent and oil.Type: GrantFiled: January 3, 2000Date of Patent: September 9, 2003Inventors: Louis P. Goodman, Dennis Bizub
-
Patent number: 6605645Abstract: Nobel polyamine compounds and polyamine compounds having carcinostatic action are provided. There are also provided anticancer agents containing as active ingredient at least one of polyamine compounds represented by the following Formula (I) or (III) and/or pharmaceutically acceptable salts thereof. Specifically, there are provided anticancer agents containing as active ingredient at least one of 1,18-bis(ethylamino)-5,14-diazaoctadecane, 1,16-bis(cyclopropylmethylamino)-5,12-diazahexadecane, 1,17-bis(cyclopropylmethylamino)-5,13-diazaheptadecane and/or pharmaceutically acceptable salts thereof.Type: GrantFiled: October 16, 2001Date of Patent: August 12, 2003Assignee: RikenInventor: Masaaki Iwata
-
Patent number: 6599941Abstract: A non-toxic, environmentally safe and easily employable insecticide and insect repellent is achieved by providing an aqueous composition incorporating ethanolamine based compounds, either independently or in combination with the ethanolamine based compounds being selected from both simple compounds and conjugated compounds. In one preferred embodiment, a highly effective composition is attained for safe, effective, direct topical application to humans and animals by employing between about 10% and 70% by volume of the entire composition of the ethanolamine-based compound. In alternate preferred embodiments, the insecticide is formulated for application to plants, trees, crops, and other vegetation to provide a composition which effectively controls bothersome insects, while being completely safe and non-injurious to the plant, tree, or crop, as well as to the flowers or fruit thereof.Type: GrantFiled: July 17, 2000Date of Patent: July 29, 2003Inventors: Lynn Sue James, Michael A. Siedman
-
Patent number: 6593372Abstract: The present invention is based on the discovery that nitric oxide (NO) is an important growth regulator in an intact developing organism. In particular, the present invention relates to a method of increasing in a mammal a population of hematopoietic stem cells which are capable of undergoing normal hematopoiesis, differentiation and maturation in hematopoietic tissue, wherein the hematopoietic tissue is contacted with multiple doses of at least one inhibitor of NO, such as one or more inhibitors of nitric oxide synthase (NOS), thereby producing hematopoietic tissue having an increased population of hematopoietic stem cells which are capable of undergoing normal hematopoiesis, differentiation and maturation. The present invention also relates to a method of increasing a population of cells in S phase in a tissue of a mammal, comprising contacting the tissue with multiple doses of at least one inhibitor (one or more) of NO, such as an inhibitor of NOS.Type: GrantFiled: October 25, 2001Date of Patent: July 15, 2003Assignee: Cold Spring Harbor LaboratoryInventors: Grigori N. Enikolopov, Natalia I. Peunova, Boris A. Kuzin, Hollis Cline, Tatyana Michurina
-
Patent number: 6586476Abstract: The present invention relates to new uses of S-2-(3-aminopropylamino)ethyl dihydrogen phosphorothioate, (amifostine) and other aminothiol compounds to treat and reverse toxicities caused by therapeutic agents, radiation treatment or diabetes. In particular, the invention provides a method for treating neurotoxicity and nephrotoxicity associated with the administration of chemotherapeutic agents.Type: GrantFiled: October 28, 1999Date of Patent: July 1, 2003Assignee: MedImmune Oncology, Inc.Inventors: Martin Stogniew, David S. Alberts, Edward H. Kaplan
-
Publication number: 20030119814Abstract: The present invention relates to novel prodrugs of pharmaceutical compounds containing one or more N—H bonds. More specifically, the present embodiment of the invention relates to prodrugs wherein sulfur-containing promoieties are attached to pharmaceutical compounds which contain one or more N—H bonds to produce prodrugs containing at least one N—S bond. These N—S bond-containing prodrugs could have optimized stability, solubility, cell membrane permeability, pharmacokinetic properties and other pharmaceutical properties over the pharmaceutical compounds from which they are formed, depending upon the nature of the promoiety. Reversion of the prodrug to the parent pharmaceutical compound occurs by the reaction of the prodrugs with thiol molecules such as cysteine, glutathione or any other thiol containing molecule.Type: ApplicationFiled: October 16, 2002Publication date: June 26, 2003Applicant: The University of KansasInventors: Victor R. Guarino, Veranja Karunaratne, Valentino J. Stella
-
Publication number: 20030096864Abstract: The present invention is substituted amines of formula (X) 1Type: ApplicationFiled: June 29, 2001Publication date: May 22, 2003Inventors: Lawrence Y. Fang, Roy Hom, Varghese John, Michel Maillaird
-
Patent number: 6548552Abstract: An absorbent article, particularly a tampon having additives that reduce toxic shock syndrome toxin (TST-1) production is disclosed. The tampon has a combination of an effective amount of at least one oxygen inhibiting agent and an effective amount of at least one surface active agent applied to: the surface of the absorbent tampon material; the surfaces of the fibers comprising the tampon; to the tampon applicator; or any combination of the foregoing. The effective amounts of the oxygen inhibiting agent and the surface active agent are sufficient to reduce the toxin production at lease about 50%, but do not negatively affect the wearer's normal vaginal flora.Type: GrantFiled: September 10, 1998Date of Patent: April 15, 2003Assignee: The Brigham and Women's Hospital, Inc.Inventors: Robert L. Deresiewicz, Dennis L. Kasper
-
Patent number: 6521591Abstract: A pharmaceutical composition suitable for enhancing muscular anabolism contains, per daily dose, at least 5 mg of anabolic initiators comprising anabolic growth factors, at least 0.12 g of protein equivalents of anabolic substrates and at least 3 g of anabolic facilitators comprising at least 1 g of creatine or its functional analog. The anabolic initiators may be derived from a non-denatured animal protein, non-denatured being defined as having an F0 of less than 3.0.Type: GrantFiled: February 10, 2000Date of Patent: February 18, 2003Assignee: N.V. NutriciaInventors: Rudolf Leonardus Lodewijk Smeets, Robert Johan Joseph Hageman
-
Publication number: 20030022867Abstract: The present invention is directed to methods of treating or protecting mucosal tissue from damage associated with radiation and/or chemotherapeutic treatment of cancers, by the topical application of amifostine and related compounds. These methods avoid the side effects of systemically applied radio/chemo protectants. The invention is also directed to treatment and prevention of infections associated with mucositis by topical application of amifostine and related compounds.Type: ApplicationFiled: March 28, 2001Publication date: January 30, 2003Applicant: MedImmune Oncology, Inc.Inventors: Martin Stogniew, Jean Bourhis
-
Patent number: 6495606Abstract: The present invention relates to novel amidino compounds of formula (I), or a salt, solvate, or physiologically functional derivative thereof; wherein R1 is selected from C1-4 alkyl, C3-4 cycloalkyl, C1-4 hydroxyalkyl, and C1-4 haloalkyl; to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use as selective inhibitors of inducible nitric oxide synthase.Type: GrantFiled: November 26, 2001Date of Patent: December 17, 2002Assignee: SmithKline Beecham CorporationInventors: Paul John Beswick, Savvas Kleanthous, Robert John Young
-
Publication number: 20020187137Abstract: A method of inhibiting the actions of S-nitrosothiols and nitric oxide which often occur in conditions such as septic shock, chronic or acute pain syndromes, uterine hypotonus, or certain gastrointestinal disorders. The method involving inhibiting the cellular binding of S-nitrosothiols to their cellular receptors or the signal transduction that would result. This is accomplished by administering an S-alkylthiol such as S-methyl-L-cysteine or S-ethyl-L-cysteine to a patient as an antagonist of S-nitrosothiol.Type: ApplicationFiled: June 12, 2001Publication date: December 12, 2002Inventors: James N. Bates, Stephen J. Lewis
-
Publication number: 20020160978Abstract: This invention provides a method for the treatment of a subject in need of treatment for osteoarthritis comprising administering to said subject an amount of an inhibitor of spermidine biosynthesis sufficient to effect a substantial inhibition of spermidine biosynthesis. This invention also provides the use of an inhibitor of spermidine biosynthesis in the treatment of a subject in need of treatment of osteoarthritis in an amount sufficient to effect a substantial inhibition of spermidine biosynthesis. This invention further provides a method of preparing a therapeutic composition for the treatment of a subject in need of a treatment for osteoarthritis and the invention further provides a method of identifying an inhibitor of spermidine biosynthesis, whereby the inhibitor is a spermidine synthase inhibitor.Type: ApplicationFiled: December 12, 2001Publication date: October 31, 2002Inventors: Dganit Bar, Elena Feinstein, Orit Segev
-
Publication number: 20020156134Abstract: Methods of inhibiting damage to proteins, lipids, and DNA by the use of penicillamines and other &agr;-amino-&bgr;,&bgr;-mercapto-&bgr;,&bgr;-dimethyl-ethane compounds as dicarbonyl scavengers is disclosed.Type: ApplicationFiled: March 7, 2002Publication date: October 24, 2002Inventors: Elaine L. Jacobson, Myron K. Jacobson, Georg T. Wondrak, Daniel Cervantes Laurean
-
Patent number: 6465517Abstract: The present invention describes a novel composition for the treatment of migraine, a common neurovascular syndrome, which can be elicited by functional and/or structural (symptomatic) disorders. This composition comprises taurine, coenzyme Q10 and additionally creatine, L-carnitine, certain vitamins and minerals, carbohydrates, proteins, fats and herbal extracts. Furthermore, the invention describes a method for the treatment of migraine.Type: GrantFiled: July 11, 2000Date of Patent: October 15, 2002Assignee: N.V. NutriciaInventor: Luutsche Van Der Zee
-
Publication number: 20020132795Abstract: The present invention relates to new uses of S-2-(3-aminopropylamino)ethyl dihydrogen phosphorothioate, (amifostine) and other aminothiol compounds to treat and reverse toxicities caused by therapeutic agents, radiation treatment or diabetes. In particular, the invention provides a method for treating neurotoxicity and nephrotoxicity associated with the administration of chemotherapeutic agents.Type: ApplicationFiled: May 3, 2002Publication date: September 19, 2002Applicant: U.S. Bioscience, Inc.Inventors: Martin Stogniew, David S. Alberts, Edward H. Kaplan
-
Patent number: 6444230Abstract: Composition in the form of an aqueous solution, useful for disinfecting hard surfaces comprises: a) from 0.0005% to 20% by weight of peracetic acid, b) from 0.001% to 45% by weight of acetic acid, c) from 0.001% to 35% by weight of hydrogen peroxide, d) from 0.0001% to 2% by weight of at least one compound of formula (I) (R1)(R2)(R3)N→O (I) e) if desired, up to 2.5% by weight of at least one nonionic surfactant, and wherein f) the weight ratio between the compound of formula (I) and the peracetic acid is less than or equal to 1, and in that g) the weight ratio between the nonionic surfactant and the peracetic acid is less than or equal to 0.2.Type: GrantFiled: November 20, 2000Date of Patent: September 3, 2002Assignees: Chemoxal SA, Societe d'Exploitation de Produits pour les Industries Chimiques SeppicInventors: Catherine Hamon Godin, Yves Gouges, Daniel Le Rouzic
-
Patent number: 6417235Abstract: Methods of inhibiting damage to proteins, lipids, and DNA by the use of penicillamines and other &agr;-amino-&bgr;,&bgr;-mercapto-&bgr;,&bgr;-dimethyl-ethane compounds as dicarbonyl scavengers is disclosed.Type: GrantFiled: April 16, 2001Date of Patent: July 9, 2002Assignee: University of Kentucky Research FoundationInventors: Elaine L. Jacobson, Myron K. Jacobson, Georg T. Wondrak, Daniel Cervantes Laurean
-
Patent number: 6410792Abstract: Amide derivatives and methods of administering the compositions to mammals to treat disorders such as obesity that are mediated by NPY and especially those mediated by NPY via the Y5 receptor.Type: GrantFiled: April 20, 1999Date of Patent: June 25, 2002Assignee: Bayer CorporationInventors: Richard D. Connell, Timothy G. Lease, Gaetan H. Ladouceur, Martin H. Osterhout
-
Patent number: 6399663Abstract: The present invention discloses highly packed polycationic ammonium, sulfonium and phosphonium lipid compounds useful for making lipid aggregates for delivery of macromolecules and other compounds into cells. They are especially useful for the DNA-dependent transformation of cells. Methods for their preparation and use as intracellular delivery agents are also disclosed.Type: GrantFiled: August 25, 2000Date of Patent: June 4, 2002Assignee: Invitrogen CorporationInventors: Alberto Haces, Valentina C. Ciccarone
-
Patent number: 6372796Abstract: The present invention is based on the discovery that nitric oxide (NO) is an important growth regulator in an intact developing organism. In particular, the present invention relates to a method of increasing in a mammal a population of hematopoietic stem cells which are capable of undergoing normal hematopoiesis, differentiation and maturation in hematopoietic tissue, wherein the hematopoietic tissue is contacted with at least one inhibitor of NO, such as one or more inhibitors of nitric oxide synthase (NOS), thereby producing hematopoietic tissue having an increased population of hematopoietic stem cells which are capable of undergoing normal hematopoiesis, differentiation and maturation. The present invention also relates to a method of increasing a population of cells in S phase in a tissue of a mammal, comprising contacting the tissue with an inhibitor (one or more) of NO, such as an inhibitor of NOS.Type: GrantFiled: May 20, 1999Date of Patent: April 16, 2002Assignee: Cold Spring Harbor LaboratoryInventors: Grigori N. Enikolopov, Natalia I. Peunova, Boris A. Kuzin, Hollis Cline, Tatyana Michurina
-
Publication number: 20020035093Abstract: The present invention provides methods of administering aminoalkyl phosphorothioate and/or aminoalkyl thiol compounds to patients receiving radiation therapy in a manner that significantly reduces or decreases the adverse or undesirable side-effects of the compounds as compared with conventional intravenous administration.Type: ApplicationFiled: February 5, 2001Publication date: March 21, 2002Applicant: MedImmune Oncology, Inc.Inventor: Martin Stogniew
-
Patent number: 6355689Abstract: The present invention relates to novel amidino compounds of formula (I), or a salt, solvate, or physiologically functional derivative thereof; wherein R1 is selected from C1-4 alkyl, C3-4 cycloalkyl, C1-4 hydroxyalkyl, and C1-4 haloalkyl; to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use as selective inhibitors of inducible nitric oxide synthase.Type: GrantFiled: November 29, 2000Date of Patent: March 12, 2002Assignee: SmithKline Beecham CorporationInventors: Paul John Beswick, Savvas Kleanthous, Robert John Young
-
Publication number: 20020019443Abstract: Methods of preventing or reducing hearing or balance loss and damage to ear cells in patients who have been exposed to toxic levels of noise are provided. These methods comprise administering an effective amount of a methionine protective agent, such as D-methionine, prior to, simultaneously with, or subsequently to exposure to noise. Combinations of these time periods can also be employed.Type: ApplicationFiled: July 23, 2001Publication date: February 14, 2002Inventor: Kathleen C.M. Campbell
-
Patent number: 6346547Abstract: Low-toxicity, highly-bioavailable, pharmaceutical antioxidant compositions for preferred oral administration to mammals are provided which have at least one amino acid-based compound of the general formula (I): A—N(Z)—CH(R1)C(O)—Q (I) wherein A is represented by the formula: XO—[C(R2)2]n— wherein n is an integer of from 1 to about 3, X is selected from the group consisting of a hydrogen atom, an acyl group and a halogenated acyl group and each R2 is independently selected from the group consisting of a hydrogen atom, an alkyl group having from 1 to about 3 carbon atoms, a hydroxyalkyl group having from 1 to about 3 carbon atoms, and CH2OX; Z is selected from the group consisting of a hydrogen atom, an alkyl group of from 1 to about 3 carbon atoms, and A; R1 is an amino acid side chain group or an amino acid side chain group which forms with R2 a single heterocyclic structure having a total of from 5 to 7 atoms in the ring; and wherein Q is a substituent sType: GrantFiled: February 8, 2000Date of Patent: February 12, 2002Assignee: Checkpoint, Genetics, Inc.Inventor: Nathan Tzodikov
-
Publication number: 20020016368Abstract: Prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders including osteoporosis.Type: ApplicationFiled: June 29, 2001Publication date: February 7, 2002Inventors: Kimberly O. Cameron, Hua Z. Ke, Bruce A. Lefker, Robert L. Rosati, David D. Thompson
-
Publication number: 20010051658Abstract: Methods of inhibiting damage to proteins, lipids, and DNA by the use of penicillamines and other &agr;-amino-&bgr;,&bgr;-mercapto-&bgr;,&bgr;-dimethyl-ethane compounds as dicarbonyl scavengers is disclosed.Type: ApplicationFiled: April 16, 2001Publication date: December 13, 2001Inventors: Elaine L. Jacobson, Myron K. Jacobson, Georg T. Wondrak, Daniel Cervantes Laurean
-
Publication number: 20010049113Abstract: Methods and compositions for treating or preventing virus infections by interfering with the activity or function of Ras, the Ras pathway, the ERK pathway, MEK1/2, PKR or eIF-2 &agr;, includes the use of agents which inhibit Ras or otherwise modulate anti-PKR activity. Also, a method of diagnosing such virus infections includes the use of cell lines that have an activated Ras pathway, including cell lines which have been transformed with a gene that activates the Ras pathway. The virus infections may be herpes virus infections and HSV-1 or HSV-2 infections in particular.Type: ApplicationFiled: May 30, 2001Publication date: December 6, 2001Inventors: Patrick W.K. Lee, Faris Farassati, An-Dao Yang
-
Patent number: 6319955Abstract: The invention relates to the use of MEK1 inhibitors to reduce tissue damage resulting from ischemia and/or reperfusion, particularly brain damage associated with ischemia resulting from stroke. Pharmaceutical compositions, kits and perfusion fluids including MEK1 inhibitors are also provided.Type: GrantFiled: October 6, 2000Date of Patent: November 20, 2001Assignee: The General Hospital CorporationInventors: Alessandro Alessandrini, Joseph Bonventre, Michael A. Moskowitz, Shobu Namura
-
Patent number: 6316269Abstract: The present invention provides screening methods for identifying compounds which induce tardive dyskinesia (TD) when administered to an animal. In particular, the methods involve assaying for intermediates and end products of reactions associated with candidate compound mediated reduction of reducible substrates. Also provided are high-throughput screening methods for determining whether compounds induce TD when administered to an animal. Further, provided are methods for treating psychoses comprising testing antipsychotic drugs to identify those which will not induce TD when administered to an animal and administering one or more such drugs to a patient in need thereof.Type: GrantFiled: October 6, 1998Date of Patent: November 13, 2001Assignee: The General Hospital CorporationInventors: Guochuan Tsai, Xudong Huang, Ashley I. Bush
-
Patent number: 6294583Abstract: The present invention describes a novel treatment for movement disorders, including tardive dyskinesia, tic disorders, Tourette's syndrome, and blepharospasm, and other focal dystonias. The treatment of the present invention utilizes agents that simultaneously act as NMDA-type glutamate receptor antagonists and GABA-A receptor agonists. Preferably these two activities are characteristic of a single agent, for example acamprosate. Alternatively, separate agents having these activities can be combined and administered together. The invention also provides a third agent that acts as a non-competitive NMDA-receptor blocking agent or ion channel blocker that augments the effect of the primary treatment. A particularly preferred ion channel blocking agent is magnesium. Alternatively, magnesium can be administered alone for prevention and treatment of movement disorders.Type: GrantFiled: November 18, 1998Date of Patent: September 25, 2001Assignee: Synchroneuron, LLCInventor: Barry S. Fogel
-
Patent number: 6290937Abstract: Disclosed are methods and compositions for regulating the melanin content of mammalian melanocytes; regulating pigmentation in mammalian skin, hair, wool or fur; treating or preventing various skin and proliferative disorders; by administration of various compounds, including alcohols, diols and/or triols and their analogues.Type: GrantFiled: May 28, 1998Date of Patent: September 18, 2001Assignee: Applied Genetics Incorporated DermaticsInventors: David A. Brown, Alexander A. Khorlin, Krystyna Lesiak, Wu Yun Ren
-
Patent number: 6245817Abstract: &agr;-alkoxy and &agr;-thioalkoxyamide compositions and methods of administering the compositions to mammals to treat disorders such as obesity that are mediated by NPY and especially those mediated by NPY via the Y5 receptor.Type: GrantFiled: April 20, 1999Date of Patent: June 12, 2001Assignee: Bayer CorporationInventors: Richard D. Connell, Timothy G. Lease, Gaetan H. Ladouceur, Martin H. Osterhout